Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Beam Therapeutics Inc.BEAM · Entity 4227 | Director | June 03, 2026 | June 05, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Beam Therapeutics Inc.
Report date June 03, 2026 · Filed June 05, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $29.55 · Expires 2036-06-03 | Direct | 19,676 |
Reported balance
After 2026-06-03 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-03 · Grant · Acquired 19,676 · Balance 19,676 F1: The option vests in full on the earlier of the first anniversary of the date of grant and immediately prior to the date of the next year's annual meeting of stockholders, subject to the reporting person's continued service to the board of directors of Beam Therapeutics Inc. through the vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests in full on the earlier of the first anniversary of the date of grant and immediately prior to the date of the next year's annual meeting of stockholders, subject to the reporting person's continued service to the board of directors of Beam Therapeutics Inc. through the vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 03, 2026 Filed Jun 5, 2026 20:05 UTC | Beam Therapeutics Inc. BEAM · Entity 4227 | GrantStock Option (Right to Buy) · Derivative | 19,676 | $0.00 Strike: $29.55 | $0.00 |
DisclosureSEC source: 0001193125-26-259536 · ownership.xml · derivative · entry 1 Fishman Mark · CIK 0001786003 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,676 Underlying: Common Stock · 19,676 shares Expires 2036-06-03 F1 · derivative.exercise_date: The option vests in full on the earlier of the first anniversary of the date of grant and immediately prior to the date of the next year's annual meeting of stockholders, subject to the reporting person's continued service to the board of directors of Beam Therapeutics Inc. through the vesting date. Read SEC document |
| June 04, 2025 Filed Jun 6, 2025 20:05 UTC | Beam Therapeutics Inc. BEAM · Entity 4227 | GrantStock Option (Right to Buy) · Derivative | 33,662 | $0.00 Strike: $17.15 | $0.00 |
DisclosureSEC source: 0000950170-25-083055 · ownership.xml · derivative · entry 1 Fishman Mark · CIK 0001786003 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,662 Underlying: Common Stock · 33,662 shares Expires 2035-06-04 F1 · derivative.exercise_date: The option vests in full on the earlier of the first anniversary of the date of grant and immediately prior to the date of the next year's annual meeting of stockholders, subject to the reporting person's continued service to the board of directors of Beam Therapeutics Inc. through the vesting date. Read SEC document |
| June 05, 2024 Filed Jun 7, 2024 20:42 UTC | Beam Therapeutics Inc. BEAM · Entity 4227 | GrantStock Option (Right to Buy) · Derivative | 23,114 | $0.00 Strike: $24.49 | $0.00 |
DisclosureSEC source: 0000950170-24-070766 · ownership.xml · derivative · entry 1 Fishman Mark · CIK 0001786003 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,114 Underlying: Common Stock · 23,114 shares Expires 2034-06-05 F1 · derivative.exercise_date: The option vests in full on the earlier of the first anniversary of the date of grant and immediately prior to the date of the next year's annual meeting of stockholders, subject to the reporting person's continued service to the board of directors of Beam Therapeutics Inc. through the vesting date. Read SEC document |
| June 06, 2023 Filed Jun 8, 2023 20:51 UTC | Beam Therapeutics Inc. BEAM · Entity 4227 | GrantStock Option (Right to Buy) · Derivative | 16,532 | $0.00 Strike: $34.33 | $0.00 |
DisclosureSEC source: 0000950170-23-027045 · ownership.xml · derivative · entry 1 Fishman Mark · CIK 0001786003 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,532 Underlying: Common Stock · 16,532 shares Expires 2033-06-06 F1 · derivative.exercise_date: The option vests in full on the earlier of the first anniversary of the date of grant and the date of the next year's annual meeting of stockholders, subject to the reporting person's continued service to the board of directors of Beam Therapeutics Inc. through the vesting date. Read SEC document |
| September 01, 2022 Filed Sep 2, 2022 20:05 UTC | Beam Therapeutics Inc. BEAM · Entity 4227 | GrantStock Option (Right to Buy) · Derivative | 10,391 | $0.00 Strike: $55.58 | $0.00 |
DisclosureSEC source: 0000899243-22-030270 · doc4.xml · derivative · entry 1 Fishman Mark · CIK 0001786003 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,391 Underlying: Common Stock · 10,391 shares Expires 2032-09-01 F1 · derivative.exercise_date: The option vests in full on the first anniversary of the date of grant, subject to the reporting person's continued service to the board of directors of Beam Therapeutics Inc. through the vesting date. Read SEC document |
| June 10, 2021 Filed Jun 14, 2021 12:02 UTC | Beam Therapeutics Inc. BEAM · Entity 4227 | GrantStock Option (Right to Buy) · Derivative | 6,877 | $0.00 Strike: $87.91 | $0.00 |
DisclosureSEC source: 0000899243-21-023471 · doc4.xml · derivative · entry 1 Fishman Mark · CIK 0001786003 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,877 Underlying: Common Stock · 6,877 shares Expires 2031-06-10 F1 · derivative.exercise_date: The option vests in full on the first anniversary of the date of grant, subject to the reporting person's continued service to the board of directors of Beam Therapeutics Inc. through the vesting date. Read SEC document |
| February 10, 2020 Filed Feb 11, 2020 14:06 UTC | Beam Therapeutics Inc. BEAM · Entity 4227 | ConversionSeries A-2 Preferred Stock · Derivative | 1,239 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-003934 · doc4.xml · derivative · entry 3 Fishman Mark · CIK 0001786003 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,239 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Upon closing of the Issuer's initial public offering, each share of Series A-1 Preferred Stock and Series A-2 Preferred Stock automatically converted into shares of Common Stock without payment or further consideration. There was no expiration date for the Series A-1 Preferred Stock or the Series A-2 Preferred Stock. F1 · kind: Upon closing of the Issuer's initial public offering, each share of Series A-1 Preferred Stock and Series A-2 Preferred Stock automatically converted into shares of Common Stock without payment or further consideration. There was no expiration date for the Series A-1 Preferred Stock or the Series A-2 Preferred Stock. F1 · price: Upon closing of the Issuer's initial public offering, each share of Series A-1 Preferred Stock and Series A-2 Preferred Stock automatically converted into shares of Common Stock without payment or further consideration. There was no expiration date for the Series A-1 Preferred Stock or the Series A-2 Preferred Stock. F1 · derivative.exercise_date: Upon closing of the Issuer's initial public offering, each share of Series A-1 Preferred Stock and Series A-2 Preferred Stock automatically converted into shares of Common Stock without payment or further consideration. There was no expiration date for the Series A-1 Preferred Stock or the Series A-2 Preferred Stock. F1 · derivative.expiration_date: Upon closing of the Issuer's initial public offering, each share of Series A-1 Preferred Stock and Series A-2 Preferred Stock automatically converted into shares of Common Stock without payment or further consideration. There was no expiration date for the Series A-1 Preferred Stock or the Series A-2 Preferred Stock. Read SEC document |
| February 10, 2020 Filed Feb 11, 2020 14:06 UTC | Beam Therapeutics Inc. BEAM · Entity 4227 | ConversionSeries A-1 Preferred Stock · Derivative | 15,768 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-003934 · doc4.xml · derivative · entry 2 Fishman Mark · CIK 0001786003 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,768 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Upon closing of the Issuer's initial public offering, each share of Series A-1 Preferred Stock and Series A-2 Preferred Stock automatically converted into shares of Common Stock without payment or further consideration. There was no expiration date for the Series A-1 Preferred Stock or the Series A-2 Preferred Stock. F1 · kind: Upon closing of the Issuer's initial public offering, each share of Series A-1 Preferred Stock and Series A-2 Preferred Stock automatically converted into shares of Common Stock without payment or further consideration. There was no expiration date for the Series A-1 Preferred Stock or the Series A-2 Preferred Stock. F1 · price: Upon closing of the Issuer's initial public offering, each share of Series A-1 Preferred Stock and Series A-2 Preferred Stock automatically converted into shares of Common Stock without payment or further consideration. There was no expiration date for the Series A-1 Preferred Stock or the Series A-2 Preferred Stock. F1 · derivative.exercise_date: Upon closing of the Issuer's initial public offering, each share of Series A-1 Preferred Stock and Series A-2 Preferred Stock automatically converted into shares of Common Stock without payment or further consideration. There was no expiration date for the Series A-1 Preferred Stock or the Series A-2 Preferred Stock. F1 · derivative.expiration_date: Upon closing of the Issuer's initial public offering, each share of Series A-1 Preferred Stock and Series A-2 Preferred Stock automatically converted into shares of Common Stock without payment or further consideration. There was no expiration date for the Series A-1 Preferred Stock or the Series A-2 Preferred Stock. Read SEC document |
| February 10, 2020 Filed Feb 11, 2020 14:06 UTC | Beam Therapeutics Inc. BEAM · Entity 4227 | ConversionCommon Stock | 17,007 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-003934 · doc4.xml · nonDerivative · entry 1 Fishman Mark · CIK 0001786003 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,007 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Upon closing of the Issuer's initial public offering, each share of Series A-1 Preferred Stock and Series A-2 Preferred Stock automatically converted into shares of Common Stock without payment or further consideration. There was no expiration date for the Series A-1 Preferred Stock or the Series A-2 Preferred Stock. F1 · price: Upon closing of the Issuer's initial public offering, each share of Series A-1 Preferred Stock and Series A-2 Preferred Stock automatically converted into shares of Common Stock without payment or further consideration. There was no expiration date for the Series A-1 Preferred Stock or the Series A-2 Preferred Stock. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.